What is Ionetix?
Ionetix operates at the intersection of nuclear physics and oncology, specializing in the development and deployment of compact superconducting cyclotrons. These systems are engineered to enable the on-site production of medical radioisotopes, a capability that significantly enhances the efficiency of PET imaging and targeted radiopharmaceutical therapies. By shifting the production model from centralized, large-scale facilities to distributed, point-of-care environments, the company provides healthcare providers with a more reliable and scalable supply of diagnostic imaging agents and therapeutic alpha emitters. This infrastructure-heavy approach positions Ionetix as a foundational player in the evolving landscape of precision medicine and cancer care.
How much funding has Ionetix raised?
Ionetix has raised a total of $31M across 2 funding rounds:
Debt
$1M
Stock/Share Issuance
$30M
Debt (2020): $1M with participation from PPP
Stock/Share Issuance (2026): $30M, investors not publicly disclosed
Key Investors in Ionetix
Undisclosed Investor
An institutional partner providing capital to support the scaling of advanced medical infrastructure.
Undisclosed Investor
A strategic backer focused on long-term growth within the high-barrier radiopharmaceutical sector.
PPP
Public-Private Partnership
What's next for Ionetix?
With this major enterprise-level funding, Ionetix is poised to accelerate the commercial rollout of its cyclotron platforms. The strategic roadmap likely involves expanding the footprint of its distributed production network, thereby reducing the logistical complexities associated with short-lived radioisotope delivery. As the demand for targeted radiopharmaceuticals continues to rise, the company is well-positioned to leverage its technological moat to capture significant market share. Future growth will likely focus on scaling manufacturing capabilities and deepening partnerships with clinical research organizations to integrate their production systems into broader oncology treatment workflows, ensuring that the next phase of development is defined by operational maturity and widespread clinical adoption.
See full Ionetix company page
